Literature DB >> 20140112

Therapies for insomnia and comorbid chronic obstructive pulmonary disease with a focus on ramelteon (rozerem).

Jack Greenberg, J B Goss.   

Abstract

Entities:  

Year:  2009        PMID： 20140112      PMCID： PMC2799137     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  37 in total

Review 1.  The safety and tolerability of zolpidem--an update.

Authors:  G Darcourt; D Pringuey; D Sallière; J Lavoisy
Journal:  J Psychopharmacol       Date:  1999       Impact factor: 4.153

2.  Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.

Authors:  Donna M Fick; James W Cooper; William E Wade; Jennifer L Waller; J Ross Maclean; Mark H Beers
Journal:  Arch Intern Med       Date:  2003 Dec 8-22

3.  Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.

Authors:  Matthew W Johnson; Patricia E Suess; Roland R Griffiths
Journal:  Arch Gen Psychiatry       Date:  2006-10

4.  Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population.

Authors:  L Mallon; J E Broman; J Hetta
Journal:  J Intern Med       Date:  2002-03       Impact factor: 8.989

Review 5.  Chronic obstructive pulmonary disease: the disease and its burden to society.

Authors:  David M G Halpin; Marc Miravitlles
Journal:  Proc Am Thorac Soc       Date:  2006-09

6.  Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40.

Authors:  J G van Manen; P J Bindels; C J IJzermans; J S van der Zee; B J Bottema; E Schadé
Journal:  J Clin Epidemiol       Date:  2001-03       Impact factor: 6.437

7.  The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease.

Authors:  Meir Kryger; Thomas Roth; Sherry Wang-Weigand; Jeffrey Zhang
Journal:  Sleep Breath       Date:  2008-06-27       Impact factor: 2.816

8.  Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia.

Authors:  Gary Zammit; Milton Erman; Sherry Wang-Weigand; Stephen Sainati; Jeffrey Zhang; Thomas Roth
Journal:  J Clin Sleep Med       Date:  2007-08-15       Impact factor: 4.062

9.  Effect of ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD.

Authors:  Meir Kryger; Sherry Wang-Weigand; Jeffrey Zhang; Thomas Roth
Journal:  Sleep Breath       Date:  2008-08       Impact factor: 2.816

10.  A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia.

Authors:  Thomas Roth; David Seiden; Sherry Wang-Weigand; Jeffrey Zhang
Journal:  Curr Med Res Opin       Date:  2007-05       Impact factor: 2.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.